Jun Jie Benjamin Seng1, Ying Lin Cheryl Tan2, Rou Wei Lim2, Hui Ting Sarah Ng2, Puay Hoon Lee2, Jiunn Wong3. 1. Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. benjamin.seng@u.duke.nus.edu. 2. Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore. 3. Department of Renal Medicine, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore.
Abstract
PURPOSE: To examine the prevalence and risk factors for hypercalcemia among non-dialysis chronic kidney disease (CKD) patients with mineral and bone disorder (MBD). METHODS: A retrospective cohort study was conducted in Singapore General Hospital, involving all CKD stage 4 and 5 pre-dialysis patients who were on treatment for MBD in June 2016. Each patient was followed up for 1 year and screened for hypercalcemia episodes. Mild, moderate and severe hypercalcemia were defined as corrected calcium of 2.47-3.00, 3.01-3.50 and ≥ 3.51 mmol/l respectively. Patients who were on dialysis, post-renal transplant, post-parathyroidectomy or had no calcium levels taken during the study period were excluded. Details related to patients' clinical information and hypercalcemia episodes were collected. Multivariate logistic regression analysis was performed to evaluate risk factors for hypercalcemia. RESULTS: Of 557 patients, 75 (13.4%) patients developed hypercalcemia. There were 120 (97.6%) mild and 3 (2.4%) moderate hypercalcemia episodes. The daily elemental calcium intake from phosphate binders and usage of vitamin D analogues did not differ between patients with and without hypercalcemia (p > 0.05). After adjusting for covariates, lower baseline iPTH level [odds ratio (OR) 0.96, 95% CI 0.93-0.99], history of hypercalcemia in past 1 year (OR 11.11, 95% CI 3.36-36.75) and immobility (OR 3.34, 95% CI 1.34-8.40) were associated with increased hypercalcemia risk. CONCLUSION: Hypercalcemia affects a significant proportion of pre-dialysis patients with MBD. More studies should be undertaken to evaluate other risk factors associated with hypercalcemia.
PURPOSE: To examine the prevalence and risk factors for hypercalcemia among non-dialysis chronic kidney disease (CKD) patients with mineral and bone disorder (MBD). METHODS: A retrospective cohort study was conducted in Singapore General Hospital, involving all CKD stage 4 and 5 pre-dialysis patients who were on treatment for MBD in June 2016. Each patient was followed up for 1 year and screened for hypercalcemia episodes. Mild, moderate and severe hypercalcemia were defined as corrected calcium of 2.47-3.00, 3.01-3.50 and ≥ 3.51 mmol/l respectively. Patients who were on dialysis, post-renal transplant, post-parathyroidectomy or had no calcium levels taken during the study period were excluded. Details related to patients' clinical information and hypercalcemia episodes were collected. Multivariate logistic regression analysis was performed to evaluate risk factors for hypercalcemia. RESULTS: Of 557 patients, 75 (13.4%) patients developed hypercalcemia. There were 120 (97.6%) mild and 3 (2.4%) moderate hypercalcemia episodes. The daily elemental calcium intake from phosphate binders and usage of vitamin D analogues did not differ between patients with and without hypercalcemia (p > 0.05). After adjusting for covariates, lower baseline iPTH level [odds ratio (OR) 0.96, 95% CI 0.93-0.99], history of hypercalcemia in past 1 year (OR 11.11, 95% CI 3.36-36.75) and immobility (OR 3.34, 95% CI 1.34-8.40) were associated with increased hypercalcemia risk. CONCLUSION:Hypercalcemia affects a significant proportion of pre-dialysis patients with MBD. More studies should be undertaken to evaluate other risk factors associated with hypercalcemia.
Entities:
Keywords:
Chronic kidney disease; Hypercalcemia; Mineral and bone disorder; Non-dialysis; Pre-dialysis
Authors: S Moe; T Drüeke; J Cunningham; W Goodman; K Martin; K Olgaard; S Ott; S Sprague; N Lameire; G Eknoyan Journal: Kidney Int Date: 2006-06 Impact factor: 10.612
Authors: Ravi Thadhani; Evan Appelbaum; Yili Pritchett; Yuchiao Chang; Julia Wenger; Hector Tamez; Ishir Bhan; Rajiv Agarwal; Carmine Zoccali; Christoph Wanner; Donald Lloyd-Jones; Jorge Cannata; B Taylor Thompson; Dennis Andress; Wuyan Zhang; David Packham; Bhupinder Singh; Daniel Zehnder; Amil Shah; Ajay Pachika; Warren J Manning; Scott D Solomon Journal: JAMA Date: 2012-02-15 Impact factor: 56.272
Authors: Suetonia C Palmer; David O McGregor; Petra Macaskill; Jonathan C Craig; Grahame J Elder; Giovanni F M Strippoli Journal: Ann Intern Med Date: 2007-12-18 Impact factor: 25.391
Authors: Jordan M Spatz; Marc N Wein; Jonathan H Gooi; Yili Qu; Jenna L Garr; Shawn Liu; Kevin J Barry; Yuhei Uda; Forest Lai; Christopher Dedic; Mercedes Balcells-Camps; Henry M Kronenberg; Philip Babij; Paola Divieti Pajevic Journal: J Biol Chem Date: 2015-05-07 Impact factor: 5.157
Authors: Menaka Pai; Nancy S Lloyd; Ji Cheng; Lehana Thabane; Frederick A Spencer; Deborah J Cook; R Brian Haynes; Holger J Schünemann; James D Douketis Journal: Implement Sci Date: 2013-01-02 Impact factor: 7.327
Authors: Saurav Ghimire; Ronald L Castelino; Nicole M Lioufas; Gregory M Peterson; Syed Tabish R Zaidi Journal: PLoS One Date: 2015-12-04 Impact factor: 3.240
Authors: Pablo Molina; Mariola D Molina; Luis M Pallardó; Javier Torralba; Verónica Escudero; Luis Álvarez; Ana Peris; Pilar Sánchez-Pérez; Miguel González-Rico; María J Puchades; José E Fernández-Nájera; Elena Giménez-Civera; Luis D'Marco; Juan J Carrero; José L Górriz Journal: J Nephrol Date: 2021-01-04 Impact factor: 3.902
Authors: Juan C Ramirez-Sandoval; Pablo Diener-Cabieses; Fabián Gutiérrez-Valle; Sofía Ley-Tapia; Santiago Pastrana-Brandes; Pablo E Galindo; Reynerio Fagundo; Mauricio Moreno-Yañez; Alfredo Adolfo Reza-Albarrán; Ricardo Correa-Rotter Journal: Int Urol Nephrol Date: 2022-03-16 Impact factor: 2.266
Authors: Paul T Kroner; Karl Mareth; Massimo Raimondo; David D Lee; Ali Alsaad; Nabeel Aslam; Peter Abader; Hani M Wadei Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27